Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phenylglycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC known ✓ | P12931 | 1/20 | 0.54 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.50 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.50 |
| ▸ | DPP4 known ✓ | P27487 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylglycine SCHEMBL304109 | 1.00 | CYP2D6 (0.54) | CYP2D6SRCLMNAMAPK1HSD17B10 | |
| Phenylglycine SCHEMBL6718142 | 1.00 | CYP2D6 (0.54) | CYP2D6SRCLMNAMAPK1HSD17B10 | |
| Phenylglycine SCHEMBL2003211 | 1.00 | CYP2D6 (0.54) | CYP2D6SRCLMNAMAPK1HSD17B10 | |
| Phenylglycine SCHEMBL4431879 | 1.00 | CYP2D6 (0.54) | CYP2D6SRCLMNAMAPK1HSD17B10 | |
| Phenylglycine SCHEMBL157180 | 0.97 | CYP2D6 (0.56) | CYP2D6SRCLMNAMAPK1HSD17B10 | |
| Phenylglycine SCHEMBL30559595 | 0.97 | CYP2D6 (0.56) | CYP2D6SRCLMNAMAPK1HSD17B10 | |
| Phenylglycine SCHEMBL159420 | 0.97 | CYP2D6 (0.56) | CYP2D6SRCLMNAMAPK1HSD17B10 | |
| Phenylglycine SCHEMBL27801493 | 0.97 | CYP2D6 (0.56) | CYP2D6SRCLMNAMAPK1HSD17B10 | |
| Phenylglycine SCHEMBL31402004 | 0.97 | CYP2D6 (0.56) | CYP2D6SRCLMNAMAPK1HSD17B10 | |
| Phenylglycine SCHEMBL11576917 | 0.97 | CYP2D6 (0.56) | CYP2D6SRCLMNAMAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111848454-A | Histone deacetylase 6 inhibitor and preparation method and application thereof | 山东大学 | 2020-10-30 | — | — | CN | claimed |
| CN-111057071-A | Preparation method of cefalexin | 刘思思 | 2020-04-24 | — | — | CN | claimed |
| EP-4551566-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2025-05-14 | — | — | EP | disclosed |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-23 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| CN-117480161-A | Novel 2, 3-dihydro-1H-pyrrolo [3,2-b ] pyridine derivatives as sigma ligands | 塔拉森调理公司 | 2024-01-30 | — | — | CN | disclosed |
| WO-2024008941-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2024-01-11 | — | — | WO | disclosed |
| WO-2023215559-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230271961-A1 | Pan-Tropic Entry Inhibitors | UNIV EMORY (US) | 2023-08-31 | — | — | US | disclosed |
| EP-3781554-B1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2023-06-28 | — | — | EP | disclosed |
| US-11649235-B2 | Pan-tropic entry inhibitors | EMORY UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| EP-0279125-B1 | TETRAHYDROPYRIDO(1,2-A)INDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1992-04-29 | — | — | EP | disclosed |
| US-4968699-A | CENTRAL NERVOUS SYSTEM; ANTIISCHEMIC AND ANTIHYPOXIC AGENTS; ACTIVE AGAINST CEREBRAL OXYGEN DEFICIENCY | BEECHAM-WUELFING GMBH & CO. (DE) | 1990-11-06 | — | — | US | disclosed |
| EP-0279125-A1 | Tetrahydropyrido(1,2-a)indole derivatives, process for their preparation and pharmaceutical compositions containing them | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1988-08-24 | — | — | EP | disclosed |
| EP-0019345-B1 | PROCESS FOR THE PREPARATION OF A (D-ALPHA-AMINO-(P-HYDROXYPHENYL)-ACETAMIDO) GROUP CONTAINING CEPHALOSPORANIC ACID DERIVATIVES | GIST-BROCADES N.V. (NL) | 1985-06-19 | — | — | EP | disclosed |
| US-4358588-A | 7-/D-ALPHA-AMINO/P-HYDROXYPHENYL/ACETAMIDO-3- CEPHEM-4-CARBOXYLIC ACID DERIVATIVES; EFFICIENCY | GIST-BROCADES N.V. (NL) | 1982-11-09 | — | — | US | disclosed |
| EP-0001133-B1 | PROCESS FOR THE PREPARATION OF 6- D-ALPHA-AMINO-(P-HYDROXYPHENYL)-ACETAMIDO PENICILLANIC ACID | GIST-BROCADES N.V. (NL) | 1982-01-20 | — | — | EP | disclosed |
| EP-0019345-A1 | Process for the preparation of a (D-alpha-amino-(p-hydroxyphenyl)-acetamido) group containing cephalosporanic acid derivatives | GIST-BROCADES N.V. (NL) | 1980-11-26 | — | — | EP | disclosed |
| US-4128547-A | TERTIARY AMINE CATALYST | GIST-BROCADES N.V. (NL) | 1978-12-05 | — | — | US | disclosed |
| US-4107203-A | SEED CRYSTALS ADDED TO SOLUTION IN PRESENCE OF METAL CHLORIDE | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649235-B2 | Pan-tropic entry inhibitors | CXCR4, CCR5, CXCL12 | SRC 941/4885SLC6A2 564/4885SLC6A4 661/4885 |
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | SRC 2427/4885SLC6A2 4756/4885SLC6A4 4412/4885 |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | SRC 2427/4885SLC6A2 4756/4885SLC6A4 4412/4885 |
| US-20230271961-A1 | Pan-Tropic Entry Inhibitors | CXCR4, CCR5, CXCL12 | SRC 971/4885SLC6A2 653/4885SLC6A4 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.